Skip to main content
Premium Trial:

Request an Annual Quote

Pharsight Forms Drug Development Alliances With AstraZeneca, Quintiles

Premium

MOUNTAIN VIEW, Calif.--Pharsight, a clinical drug development software provider and consultancy here, has formed two partnerships: one with AstraZeneca R&D Molndal, of Sweden, and a broader one with Quintiles Transnational, a Research Triangle Park, NC-based provider of product development and commercialization services to the pharmaceutical industry.

The goal of the AstraZeneca alliance is to jointly deploy Pharsight's trial design software and methodologies for drug development to AstraZeneca's clinical development processes in a specific therapeutic area.

The Quintiles deal is part of a larger Pharsight partnership among organizations offering clinical development and scientific services.

Filed under

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.